CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Incyte Corporation
Merck Sharp & Dohme LLC
Beijing Biotech
Pfizer
AbbVie
Sellas Life Sciences Group
AvenCell Therapeutics, Inc.
Caribou Biosciences, Inc.
Tempus AI
Gamida Cell ltd
Ascentage Pharma Group Inc.
Prelude Therapeutics
Orca Biosystems, Inc.
Pfizer
Miltenyi Biomedicine GmbH
CellCentric Ltd.
BeOne Medicines
Kura Oncology, Inc.
Incyte Corporation
Sichuan Baili Pharmaceutical Co., Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.
Biotroy Therapeutics
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Indapta Therapeutics, INC.
Cogent Biosciences, Inc.
Tr1X, Inc.
JaxBio Ltd
Hangzhou Sumgen Biotech Co., Ltd.
AbbVie
Ipsen
Munich Leukemia Laboratory
Munich Leukemia Laboratory
Takeda
Vincerx Pharma, Inc.
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
AbbVie
Mundipharma Research Limited
Kyowa Kirin Co., Ltd.
MitoImmune Therapeutics
Pack Health
Pfizer
Newave Pharmaceutical Inc
Shenzhen TargetRx Co., Ltd.
Prelude Therapeutics
Sumitomo Pharma America, Inc.
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
AstraZeneca
Bristol-Myers Squibb